SCHEDULE: OnKure Therapeutics: Stakeholder Holdings Update

Several Biotechnology Value Funds and Mark N. Lampert have updated their beneficial ownership of OnKure Therapeutics' Class A Common Stock, reporting holdings as of May 27, 2026.

Summary

• This filing is an amendment to Schedule 13G, detailing the beneficial ownership of OnKure Therapeutics, Inc. Class A Common Stock by various entities associated with Biotechnology Value Fund (BVF) and Mark N. Lampert.
• As of May 27, 2026, the reporting persons and a managed account held pre-funded warrants exercisable for 2,147,534 shares of Class A Common Stock.
• These pre-funded warrants are subject to a 'blocker' provision, limiting exercise if beneficial ownership would exceed 4.9% of outstanding shares.
• As of the filing date, the blocker prevented the exercise of these warrants.
• Specific holdings reported include: BVF (1,095,373 shares, 2.7%), BVF2 (854,705 shares, 2.1%), Trading Fund OS (153,595 shares, <1%).
• Various GP and management entities (BVF GP, BVF2 GP, Partners OS, BVF GPH, Partners, BVF Inc.) are deemed to beneficially own shares through their relationships with the primary funds.
• Mark N. Lampert, as a director and officer of BVF Inc., is deemed to beneficially own 2,134,908 shares (5.3%).
• The percentages are based on 40,395,480 shares outstanding as of May 4, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of beneficial ownership and does not provide new operational or financial information about the company itself.

Positives

• The reporting persons collectively hold a significant stake in OnKure Therapeutics, indicating continued investment interest.
• The disclosure provides clarity on the beneficial ownership structure and the extent of holdings by various related entities.

Negatives

• The 'Pre-Funded Warrants Blocker' limits the immediate exercise of a substantial number of shares, capping potential ownership increases.
• The filing does not provide any financial performance data or operational updates for OnKure Therapeutics, focusing solely on ownership.

Risks

• The 'Pre-Funded Warrants Blocker' poses a risk to the reporting persons' ability to increase their stake beyond 4.9% without triggering ownership limits.
• The reliance on pre-funded warrants and potential exercise limitations could indicate a lack of immediate liquidity or a strategic holding pattern.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding OnKure Therapeutics' future performance. It solely reports on current beneficial ownership as of a specific date.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard for institutional investors and significant holders to report their stakes in public companies. The involvement of Biotechnology Value Fund suggests active participation in the biotechnology sector, which is characterized by significant capital deployment and strategic investment in emerging companies.

Stakeholder Impact

• Shareholders: Provides transparency on significant ownership stakes and potential future share movements by large holders.
• Management of OnKure Therapeutics: Informs management about the holdings and potential influence of major investors.
• Potential Investors: Offers insight into the investment strategies and positions of funds like Biotechnology Value Fund.

Next Steps

• The reporting persons will continue to monitor their beneficial ownership levels in relation to the 4.9% 'blocker' for pre-funded warrant exercise.
• Future amendments to Schedule 13G will be filed if there are material changes in beneficial ownership.

Key Dates

Keywords

Schedule 13G, OnKure Therapeutics, Biotechnology Value Fund, Mark N. Lampert, Beneficial Ownership, Class A Common Stock, Pre-funded Warrants, SEC Filing, Investment Holdings